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Introduction
Ultrasound (US) imaging is an unsurpassed guide for interventional 
procedures first and foremost because it is in real time. In addition, 
it is rapid and convenient, all puncture directions are possible and it 
allows continuous visualization of the needle tip during needle in-
sertion. There is no ionizing radiation and the equipment is mobile 
and relatively inexpensive. Because of these advantages, US-guided 
interventional procedures have achieved widespread use [1, 2].
US-guided percutaneous biopsy of focal liver lesions (FLLs) is a 
classic interventional procedure performed by almost all radiology 
units. Typically, an incidental focal finding on US or a focal indetermi-
nate lesion diagnosed on CT, MRI or PET/CT is referred for contrast-en-
hanced US (CEUS). If still indeterminate, US-guided biopsy might be 
considered for the final diagnosis. With a 1.2 mm (18 gauge) auto-
matic cutting needle, a histologic tissue core can be obtained and 
gives the pathologist optimal conditions for further tissue processing 
including specialized oncologic techniques (immune-histochemical 
analysis). Fine needle aspiration (cytology) of FLLs is often sufficient 
to demonstrate malignancy but insufficient to assess specific tumor 
markers and perform gene analysis [3].
The development of microbubble US contrast agents has over-
come some of the limitations of standard US for FLLs and enables 
the display of the parenchymal perfusion and microvasculature. 
The enhancement patterns in an FLL can be studied over time dur-
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AbsTr ACT
US-guided percutaneous biopsy of focal liver lesions (FLL) is a 
classic interventional procedure performed by almost all radi-
ology units. Typically, an incidental focal finding on US or a 
focal indeterminate lesion diagnosed on CT, MRI or PET/CT is 
referred for US-guided biopsy for final diagnosis. The introduc-
tion of microbubble US contrast agents has overcome some of 
the limitations of standard US in diagnosing FLLs by displaying 
the microvasculature together with the US morphology, which 
has increased both the sensitivity and the specificity. The com-
bination of CEUS and intervention is facilitated by newer US 
equipment providing split-screen mode, which displays the 
CEUS mode alongside the standard US mode simultaneously 
on a single monitor. The puncture line is displayed in both 
modes as well as on the monitor. The interventional device (i. e., 
biopsy needle) is typically best visualized in the standard US 
mode, while the characteristic tissue pattern in an FLL is typi-
cally best visualized in CEUS mode. There are 3 main categories 
in which CEUS has an impact on US-guided biopsy of FLLs: • 
CEUS improves the visualization of FLLs • CEUS improves the 
quality of the biopsy specimen from an FLL • CEUS reduces the 
need for US-guided biopsy of an FLL In the two first categories, 
CEUS is utilized simultaneously with US-guided biopsy to en-
sure correct needle targeting. In the last category, US-guided 
biopsy of the FLL becomes superfluous as a result of the CEUS 
examination.
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ing all vascular phases (arterial, portal venous and late phases), in 
a similar fashion to contrast-enhanced CT and MRI but in real time 
and under the full control of the US operator [4]. Several studies 
have demonstrated that contrast-enhanced US (CEUS) increases 
sensitivity and specificity in diagnosing FLLs to the same level that 
can be achieved by contrast-enhanced CT and MRI [5, 6]. Further-
more, allergic and severe reactions induced by CEUS are rare [7]. 
There are a few limitations when using CEUS for diagnosing FLLs, 
such as deeply located lesions and advanced fatty liver.
The combination of US contrast agents and intervention is facil-
itated by newer US equipment, providing the split-screen mode, 
which displays the CEUS mode alongside the standard US mode si-
multaneously on a single monitor. The puncture line is displayed in 
both modes as well on the monitor. The interventional device (i. e. 
biopsy needle) is typically best visualized in the standard US mode, 
whereas the characteristic tissue pattern in an FLL is typically best 
visualized in CEUS mode.
This pictorial review focuses on the impact of CEUS on US-guided 
biopsy of FLLs [8]. It is based on a literature search of PubMed per-
formed in June 2018. The amount of scientific work in this field is still 
limited, but a clear tendency and some obvious advantages with 
CEUS-guided biopsy will be demonstrated. Several illustrative cases 
(figures and links to videos) will be presented as well. In our opinion, 
there are 3 main categories that show the impact of CEUS on US-guid-
ed biopsy of FLLs:
 ▪ CEUS improves the visualization of FLLs
 ▪ CEUS improves the quality of the biopsy specimen from an FLL
 ▪ CEUS reduces the need for US-guided biopsy of an FLL
In the two first categories, CEUS is utilized simultaneously with 
US-guided biopsy to ensure correct needle targeting which, in a 
recent multi-center study, was needed in 2.6 % of all US-guided bi-
opsies of FLLs [9]. In the last category, US-guided biopsy of the FLL 
becomes superfluous as a result of the CEUS examination.
▶Fig. 1 Improved visualization of liver metastasis after CEUS. Patient with disseminated breast cancer and liver metastases seen on recent PET/CT. On 
fundamental US (image to the left), the metastasis cannot be seen. In CEUS mode (image to the right) a clearly depicted lesion (metastasis) is seen be-
tween the 2 calipers located close to the right kidney (Fig 1a). Puncture line has been applied; still the metastasis is only visible in CEUS mode (Fig. 1b).
a
b
  VIDEO 1
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Review and Discussion
CEUS improves the visualization of FLLs
Most FLLs are clearly visualized on standard B-mode US and a biop-
sy can therefore be performed successfully with guidance by stand-
ard US in most cases. However, some FLLs might be difficult or im-
possible to see on standard US due to a lack of tissue contrast be-
tween the lesion and the surrounding normal liver tissue, thus an 
isoechoic lesion. These patients are often referred after a suspicious 
finding on other image modalities (CT, MRI or PET/CT), and a 
US-guided biopsy is requested for achieving the final diagnosis. In 
such cases, CEUS may be helpful in 2 different ways: 1. the suspi-
cious lesion seen on previous imaging may turn from invisible or 
inconspicuous on standard US to “clearly visualized” on CEUS im-
aging; and 2. Additional FLLs that are potentially more easily acces-
sible for biopsy may be visualized and biopsied under CEUS visual-
ization and guidance.
In 2004, Schlottmann et al. in a small series of 12 patients with FLLs 
that were invisible on standard US demonstrated that CEUS made all 
(100 %) of the lesions visible. The following CEUS-guided biopsy gave 
the final diagnosis in 11 (92 %) of the 12 cases [10]. In a recent retro-
spective study by Partovi at al., 26 patients with poorly visualized or 
invisible FLLs on standard US were referred for CEUS-guided biopsy as 
an alternative to CT-guided biopsy. In 23 (88 %) of the patients, 
CEUS-guided biopsy was reported to be successful [11]. A prospective 
nonrandomized study by Yoon et al. included 44 patients with FLLs 
that were not able to be confidently located for biopsy on standard 
US. CEUS-guided biopsy was possible in 39 patients (89 %), and the bi-
opsy yielded the final diagnosis in 38 patients (86 %) [12]. In a prospec-
tive study by Park et al., 66 patients were enrolled for US-guided biop-
sy or US-guided RF ablation. CEUS increased the detection rate of FLLs 
from 77 % (standard US) to 92 % and a success rate of CEUS-guided bi-
opsy of 95 % was reported [13]. Finally, Sparchez et al. reported a pro-
spective study with 171 patients with FLLs (seen on CT or MRI) referred 
for US-guided biopsy and randomized into 2 groups: One group had 
liver biopsy guidance by standard US and the other group underwent 
CEUS-guided biopsy. A correct pathological diagnosis could be 
reached in 97 % of the CEUS group and 81 % of the standard US group. 
▶Fig. 2 CEUS improves the quality of the biopsy specimen from FLLs. In a patient with disseminated malignant melanoma, a new biopsy from liver metas-
tasis was requested by the oncologists. On fundamental US, a 6 cm lesion is seen in the left liver lobe (segment 4) close to the gall bladder (Fig. 2a). After 
CEUS, most of the liver metastasis is seen to be necrotic and avascular, and only the right part of the tumor is vascularized (where the puncture line has been 
applied just before percutaneous biopsy guided by CEUS) (Fig. 2b).
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Especially in patients with cirrhosis, CEUS improved tumor visualiza-
tion significantly and thereby the diagnostic accuracy [14].
The two latter studies confirm that standard US is most often 
sufficient as the primary biopsy-guiding modality and CEUS guid-
ance can be reserved for cases with poor or no visibility on stand-
ard US. In cases in which CEUS mode does not provide satisfying 
visualization of an FLL, other US techniques, such as fusion imaging 
or elastography, may be considered [15, 16]. Alternatively, biopsy 
of an FLL that is “invisible” on CEUS can be performed under CT or 
MRI guidance.(▶Fig. 1, Video 1)
▶Fig. 3 Typical hemangioma on US confirmed with CEUS. Incidental finding of a 3 cm echogenic, homogeneous and well demarcated mass in the 
left liver lobe (Fig. 3a). In CEUS mode the monitor shows fundamental US mode to the left and contrast US mode to the right. In the arterial phase 
(after 20 s), characteristic rim enhancement is demonstrated around the hemangioma (Fig. 3b). After 60 s (late phase), the rim enhancement is 
progressing in a centripetal direction (Fig. 3c). After 120 s, the rim enhancement is further progressing in a centripetal direction to a partial fill-in 
(Fig. 3d). Thus, this is an example of a CEUS examination that made US-guided biopsy superfluous.
a
b
c
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▶Fig. 4 Typical FNH demonstrated on CEUS. Primarily identified on CT as a focal indeterminate hypervascular lesion in the right liver lobe (Fig. 4a). 
On fundamental US, the lesion was slightly hypoechoic (Fig. 4b). In CEUS mode, in the arterial phase (after 10 s) a characteristic spoke-wheel pattern 
is seen (Fig. 4c). In the late phase, the FNH becomes almost isovascular on CEUS (Fig. 4d). Thus, this is an example of a CEUS examination that made 
US-guided biopsy superfluous.
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in the target lesion, inadvertent sampling from necrotic parts of 
the tumor can be reduced.
In a prospective study, Wu et al. included 186 patients with un-
certain FLLs. Patients were randomized to a standard US or a CEUS 
pre-biopsy examination looking for tumor enhancement and via-
bility. The diagnostic accuracy of the initial biopsy was significant-
ly higher in the CEUS group than in the standard US group (95 % 
versus 87 %). It should be noted that all biopsies were performed 
guided solely by standard US. An even higher diagnostic accuracy 
was reported in patients with small FLLs < 2 cm, which is surprising 
since tumor necrosis is often associated with larger tumors. How-
ever, we believe that the higher diagnostic accuracy was a result of 
improved visualization by CEUS [17]. In a prospective study, Eso et 
al. reported significantly fewer cases of insufficient biopsy materi-
al from FLLs when the biopsy was guided by CEUS rather than by 
standard US [18]. Finally, the prospective study by Sparchez already 
mentioned above reported a significant increase in diagnostic ac-
curacy when large FLLs > 6 cm underwent CEUS-guided biopsy 
probably due to a reduced number of insufficient biopsies contain-
ing necrotic material [14].
Improvement of biopsy quality due to the use of CEUS guidance 
has also been demonstrated in non-hepatic tumors in several papers 
[19–21]. There is no evidence to support and justify the routine use 
of US contrast agents in all US-guided biopsies of FLLs because of 
cost and time. However, we recommend CEUS guidance when a 
re-biopsy is requested due to either an insufficient initial biopsy with 
necrotic material or insufficient visualization, which might be rele-
vant in a small percentage of all biopsies [9]. (▶Fig. 2 , Video 2)
▶Fig. 5 Typical focal fatty change in B mode and CEUS mode. In B mode, a hypoechoic lesion with a patchy, geographic pattern appearance is 
located anterior to the portal vein (Fig. 5a). In CEUS mode, in the late phase (after 60 s) the lesion in contrast mode (image to the right) is isovascular 
– typical for focal fatty change (Fig. 5b). Thus, this is an example of a CEUS examination that made US-guided biopsy superfluous.
a
b
  VIDEO 5
 
CEUS improves the quality of the biopsy specimen 
from an FLL
Sometimes, the pathology report from an FLL biopsy may simply 
read as necrotic or insufficient material. Especially large tumors 
(both hepatic and non-hepatic) tend to contain necrotic and lique-
fied areas – often located centrally due to perfusion insufficiency. 
A repeated biopsy procedure is then warranted to obtain decisive 
and viable material, and increased attention is paid to avoid sam-
pling from necrotic areas within the lesion. With CEUS, tissue vas-
cularization and thereby viability can be evaluated effectively. By 
directing the biopsy needle toward contrast-enhanced areas with-
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CEUS reduces the need for US-guided biopsy  
of an FLL
Standard US of the liver is sufficient for characterizing many benign 
FLLs, such as cysts, hyperechoic hemangiomas, typically located 
focal fat accumulations or fatty sparing. Atypical findings, on the 
other hand, often require other modalities such as CT, MRI, and 
PET/CT and/or US-guided biopsy to reach a conclusive diagnosis. 
When it comes to malignant FLLs, US-guided biopsy has been al-
most a routine procedure to reach the final diagnosis. Percutane-
ous biopsy of benign and malignant FLLs is still regarded as the gold 
standard for the final diagnosis. However, the introduction of CEUS 
has significantly improved the ability to characterize FLLs based on 
imaging alone, thus giving an almost conclusive and final diagno-
sis without the need for biopsy and histologic proof. There is now 
substantial scientific evidence to support this statement in the form 
of guidelines, systematic reviews and meta-analyses [22–27]. Thus, 
▶Fig. 6 Typical liver metastases in B mode and CEUS mode. In B mode, 2 hypoechoic and suspicious lesions of 15–20 mm are visualized in the liver 
(Fig. 6a). In the arterial phase (after 20 s), the 2 FLLs are hyperenhancing (Fig. 6b). In the late phase (after 1–2 min), the 2 FLLs are hypoenhancing 
(washout) (Fig. 6c). The finding was confirmed in other imaging modalities and the patient was operated (liver resection) without histologic confir-
mation.
a
b
c
according to the EFSUMB Guidelines on Interventional Ultrasound 
[28], the indications for US-guided FLL biopsy are:
 ▪ Diagnosis not established by any imaging method
 ▪ Lesion immune-histochemical analysis needed for therapy
 ▪ Histological assessment needed for a therapeutic decision 
(e. g. hepatocellular carcinoma vs. cholangiocarcinoma).
Some of the typical characteristics of FLLs seen on CEUS examina-
tion are as follows:
Benign FLLs:
Hemangioma
US finding of an atypical hemangioma requires further imaging, pos-
sibly biopsy. CEUS has markedly improved the accurate diagnosis of 
hemangiomas, which is now possible in about 95 % of cases [5]. The 
typical CEUS features of a hemangioma are peripheral nodular en-
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hancement in the arterial phase (the rim sign) to partial or complete 
fill-in progressing in a centripetal direction (▶Fig. 3, Video 3). The 
filling-in lasts from seconds to minutes and is more rapid in smaller 
lesions. Enhancement is sustained through the late phase [22]. 
Thrombosed hemangiomas can be confused with malignancies be-
cause of the lack of enhancement in all vascular phases in the throm-
bosed portions, which may be misinterpreted as washout if only the 
late phase is studied [29].
Focal nodular hyperplasia (FNH)
On CEUS, FNH typically appears as a hyperenhancing homogene-
ous lesion in all phases. Hyperenhancement is obvious and usually 
marked in the arterial phase, with rapid fill-in from the center out-
wards (70 %), the so-called spoke-wheel pattern or with an eccen-
tric vascular supply (30 %) [30]. During the portal venous and late 
phases, FNH may remain slightly hyperenhancing or become isoen-
hancing and a centrally located scar may be seen. It is hypoenhanc-
ing in the late phase [22] (▶Fig. 4, Video 4)
Focal fatty change, either fat infiltration or fatty sparing, may sim-
ulate masses on standard US. Differential diagnosis is important, es-
pecially in patients with underlying malignant disease or with an atyp-
ical location of suspected focal fatty changes. On CEUS, focal fatty 
change shows exactly the same enhancement patterns as the adja-
cent liver parenchyma in all phases [22, 31]. (▶Fig. 5, Video 5)
Malignant FLLs:
Metastases
Liver metastases can be detected and characterized reliably as hy-
poenhancing lesions during the portal venous and late phases, with 
very few exceptions. Washout starts early, usually in the portal ve-
nous phase, and is marked. Thus, they appear as “black foci” against 
the background of the uniformly enhanced normal liver parenchy-
ma [22]. (▶Fig. 6, Video 6)
Hepatocellular carcinoma (HCC)
Typical finding is an intense arterial uptake followed by washout of 
contrast in the venous and late phase. Unfortunately, however, be-
tween 50 % and 70 % of well differentiated HCCs -corresponding to 
approximately 10 %–15 % of HCCs in the cirrhotic population - may 
not demonstrate this typical enhancement pattern [22, 32]. Fur-
thermore, overlapping characteristics have been demonstrated in 
CEUS imaging of HCC and cholangiocarcinoma [33]. Consequent-
ly, sole use of CEUS in the detection of HCC and cholangiocarcino-
ma cannot be recommended and other imaging modalities or ul-
timately biopsy should be considered.
In our hospital, we now only perform US-guided biopsy of “benign” 
FLLs if CEUS imaging together with other imaging modalities (CT, MRI, 
PET/CT) and the clinical history make the lesion appear atypical and 
suspicious for malignancy. Regarding obviously malignant FLLs, we 
only perform biopsy by request and after evaluation by a multidisci-
plinary team. A patient with liver metastases based on imaging and 
deemed resectable by surgeons will go directly to surgery without bi-
opsy since surgeons prefer to eliminate the small risk of seeding in the 
puncture tract [34]. Patients with multiple liver metastases are re-
ferred to oncologic treatment and the need for metastasis biopsy de-
pends on several factors including the need for immune-histochemi-
cal analysis.
Conclusion
CEUS is a helpful tool when biopsy of FLLs is requested or consid-
ered, especially when the lesion is inconspicuous or invisible on 
standard US and/or when the initial biopsy was insufficient due to 
necrotic material. Furthermore, CEUS has improved FLL character-
ization significantly and has thereby made many biopsies of benign 
and malignant FLLs superfluous.
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